For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT03412643
An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage
Contact Name:
Kathryn Tower
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
IRB number :
1412979
Study Number:
NSABP FB-12
Phone:
Fax:
ANHL1931: A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination with Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma
Contact Name:
Study Type:
Oncology - Leukemia/Lymphoma/Myeloma
Study Status:
Open to Accrual
Principal investigator:
Ari Elman, MD
IRB number :
2036013
Study Number:
ANHL1931
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT04759586
ASCENT-05: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy
Contact Name:
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Robert Donegan, MD
IRB number :
2094429
Study Number:
ASCENT-05 (G2309)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05633654
Cambria-1: A Study of Camizestrant in ER+/​HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine Therapy
Contact Name:
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Priyanka Mittar, DO
IRB number :
2058558
Study Number:
Cambria-1 (G2306)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05774951
Cambria-2: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer
Contact Name:
Study Type:
Oncology - Breast
Study Status:
Open to Accrual
Principal investigator:
Priyanka Mittar, DO
IRB number :
2084381
Study Number:
Cambria-2 (G2308)
Phone:
Fax:
For more information about this clinical trial, please visit the following link: https://clinicaltrials.gov/study/NCT05952557